A Prospective, Single-arm, Clinical Trial of Electrospun Fiber Matrix (Restrata) in the Treatment of Surgical Defects Secondary to Resection of Malignant Cutaneous Neoplasms

Recruiting now

Conditions studied: Surgical Wound

In brief

The goal of this observational prospective study is to evaluate wound healing outcomes in resection wounds resulting from surgical removal of cutaneous malignancies treated with a synthetic electrospun fiber matrix. This study intends to quantify the time from initial resection and product application to time of complete granulation of the wound bed in weeks.

Key facts

Study ID

NCT06578650

Run by

Acera Surgical, Inc.

People needed

34

Starts

2024-10-31

Expected to finish

2027-10-01

Last updated by the study team

2026-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is at least 18 years old
• Patient plans to undergo surgical resection of a cutaneous neoplasm
• Patient is willing and capable of complying with all protocol requirements
• Patient or legally authorized representative (LAR) is willing to provide written informed consent prior to participation in study
• Post-resection surgical wound with a surface area of ≥4 cm2 and ≤ 36cm2

You may not qualify if…

• Inability to give informed consent or to complete the procedures required for study completion
• Patient has been previously enrolled into this study, or is currently participating in another drug or device study that has not reached its primary endpoint
• Patient is pregnant, breast feeding or planning to become pregnant
• Patient has a known allergy to resorbable suture materials, e.g. Polyglactin 910 (PGLA), Polydioxanone (PDS)
• Patients receiving any immunotherapy, radiation, or chemotherapy within the past four weeks prior to resection surgery.
• Patient has a life expectancy less than six months as assessed by the investigator
• Patient has an additional non-study related wound within 3 cm of the study wound
• Study wound is located on the hands or feet
• Patient has been diagnosed with osteomalacia
• Resection defect from a squamous cell carcinoma arising from a chronic wound
• Patient has an uncontrolled thyroid disorder
• Hgb A1c > 12% within 3 months prior to enrollment in patients with a known history of diabetes
• Patient has a BMI > 34.9
• Patient has used any tobacco product within the past 30 days prior to surgery
• Patients with chronic kidney disease on peritoneal or hemodialysis, or with an estimated glomerular filtration rate less than 15mL/min
• Patients with severe liver disease with active cirrhosis defined as a gross ascites upon clinical exam or a Model for End-stage Liver Disease (MELD)-Na score greater than 15
• Patient not in reasonable metabolic control in the judgement of the investigator
• Patient has a known history of poor compliance with medical treatment
• Patient has a history of radiotherapy to wound bed of interest
• Patient has been diagnosed with at least one of the following autoimmune connective tissue diseases: lupus, vasculitis, sickle cell, or uncontrolled rheumatoid arthritis
• Active infection, undrained abscess, or critical colonization of the wound with bacteria in the judgement of the investigator

Where it is running

• University Nevada - Las Vegas — Las Vegas, Nevada, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.